Eli Lilly stock holds after 2025 revenue and profit growth

Eli Lilly & Co. (US5324571083) is supported by a 2025 financial base of $45.0 billion in revenue and $10.6 billion in net income, while the shares closed at $766.33 on 23 July 2026. The latest annual report also showed adjusted earnings per share of $22.49 for 2025, up from $12.13 in 2024, a comparison that highlights the scale of the profit step-up.

2025 numbers set the tone

The company reported 2025 revenue of $45.0 billion, compared with $34.1 billion in 2024, according to its annual report. Net income reached $10.6 billion in 2025, versus $5.2 billion a year earlier, and the gross margin improved as the drug mix shifted toward higher-value products.

Adjusted earnings per share rose to $22.49 from $12.13, a gain of 85.4% year over year. That kind of move matters because it gives the market a clearer profit benchmark than a simple sales comparison alone.

Shares near their recent level

The stock finished at $766.33 on 23 July 2026, which leaves it well above the companys 2025 profit base in valuation terms and keeps the market focused on whether earnings can sustain that level. The share price itself is the cleanest current market marker in the available evidence.

For investors, the key question is not the sales base alone but whether 2026 earnings can keep pace with the 2025 jump in adjusted EPS and net income. A higher revenue base without matching profit growth would be a different story.

Revenue up 31.9%

Eli Lillys 2025 revenue of $45.0 billion was 31.9% higher than the $34.1 billion reported for 2024. That is a quantified comparison, and it shows that the company entered 2026 with a stronger operating runway than in the prior year.

The annual report also showed that the company ended 2025 with research and development spending of $13.3 billion, compared with $9.4 billion in 2024. That level of investment explains part of the pressure on expenses, but it also signals continued support for the pipeline.

Diabetes and obesity

The core product mix remains centered on diabetes and obesity therapies, which have become the main revenue drivers in recent reporting. That matters because the companys top-line growth and margin profile are closely tied to a narrow set of high-demand products.

Mounjaro and Zepbound remain the most relevant commercial references in that mix, and the market continues to track their contribution through quarterly revenue updates and prescription trends. Those products are also the clearest link between unit growth and the 2025 earnings step-up.

Stock level in context

With the shares at $766.33 on 23 July 2026, the market is still pricing in strong execution beyond the 2025 base of $45.0 billion in revenue and $22.49 in adjusted EPS. The evidence points to a company that has already moved from a growth story to a large-scale earnings story, which raises the bar for every later quarter.

That makes the next reported quarter important not because of a headline rumor, but because the company has to defend a valuation built on very large 2025 numbers. If revenue growth slows while EPS growth normalizes, the stock response could be more measured than in 2025.

Mounjaro and Zepbound

Mounjaro and Zepbound are the product names that best explain the companys revenue power in 2025. They sit at the center of the diabetes and obesity franchise that helped lift revenue to $45.0 billion and adjusted EPS to $22.49.

The commercial importance of those products is not abstract: the 2025 report shows that Eli Lilly turned strong demand into a much larger profit base, with net income of $10.6 billion after $5.2 billion in 2024. That is the clearest operating link between the product mix and the stock story.

23 July 2026 close

At $766.33 on 23 July 2026, Eli Lilly stock remained tied to the companys 2025 operating momentum and to expectations that the current earnings base can be defended. The price is the most recent dated market value in the available evidence, and it sits beside a much larger 2025 profit profile than the year before.

The combination of $45.0 billion in 2025 revenue, $10.6 billion in net income, and $22.49 in adjusted EPS is what frames the stock now. Those numbers, rather than any single day of trading, define the current setup.